The Alkermes ALKS 3831 development program is part of our ongoing commitment to develop new therapeutic options for adults living with serious mental illness.
Cedar Health Research, located in Dallas and Irving, is currently enrolling candidates in two clinical trials to evaluate the safety and tolerability of Rimegepant